Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country-Reference-Cited by-同舟云学术

Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country

Published:2022-05-03 Issue:11 Volume:13 Page:1676-1683
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

How Soon Hin¹,Tho Lye Mun²,Liam Chong Kin³,Hasbullah Harissa H.⁴⁵^ORCID,Ho Gwo Fuang³,Muhammad Nor Ibtisam⁵,Poh Mau Ern³^ORCID,Ho Kean Fatt⁶,Thiagarajan Muthukkumaran⁵,Samsudin Azlina⁷,Omar Azza⁸,Ong Choo Khoon⁹,Pang Yong Kek³,Soon Sing Yang¹⁰

Affiliation:

1. Kulliyyah of Medicine International Islamic University Malaysia Kuantan Malaysia

2. Department of Clinical Oncology Beacon Hospital Petaling Jaya Malaysia

3. Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

4. Oncology Unit, Faculty of Medicine Universiti Teknologi Mara Sungai Buloh Malaysia

5. Oncology and Radiotherapy Department General Hospital Kuala Lumpur Kuala Lumpur Malaysia

6. Mount Miriam Cancer Hospital Penang Malaysia

7. Hospital Sultanah Nur Zahirah Kuala Terengganu Malaysia

8. Respiratory Unit, Medical Department Hospital Raja Perempuan Zainab II Kota Bharu Malaysia

9. Gleneagles Penang George Town Malaysia

10. Sarawak Heart Centre Kota Samarahan Malaysia

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14442

Reference21 articles.

1. AzizahAM HashimahB NirmalK Siti ZubaidahAR PuteriNA NabihahA et al.Malaysia National Cancer Registry Report (MNCR) 2012‐2016. Putrajaya (Malaysia): Ministry of Health (Malaysia); 2019.

2. Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

4. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

5. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study;Pathology;2023-12

2. Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022;Cancer Management and Research;2023-08

3. Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country;Cancer Management and Research;2023-01